Are dosing adjustments required for colchicine in the elderly compared with younger patients?

Advances in Therapy

Volumn 29, Issue 6, 2012, Pages 551-561

  Wason, Suman ^a   Faulkner, Robert D ^a   Davis, Matthew W ^a  

^a Mutual Pharmaceutical Company Inc   (United States)

Author keywords

Age; Bioavailability; Colchicine; Dosing; Pharmacokinetics

Indexed keywords

COLCHICINE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEADACHE; HEART RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NOSE CONGESTION; PLASMA CONCENTRATION-TIME CURVE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TANDEM MASS SPECTROMETRY; TINNITUS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; COLCHICINE; CONTINENTAL POPULATION GROUPS; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; GOUT SUPPRESSANTS; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84866479843     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-012-0028-6     Document Type: Article

References (12)

1. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143:499-516. (Pubitemid 41379398)
2. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3:443-9. (Pubitemid 47193550)
3. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63:3136-41.
4. Colcrys® (colchicine, USP) tablets for oral use: Prescribing information, 14 March 2012. Available at: Www.colcrys.com/assets/pdf/COLCRYS- Full-Prescribing-Information.pdf. Accessed Apr 25 2012.
5. Niel E, Schermann J-M. Colchicine today. Joint Bone Spine. 2006;73:672-8. (Pubitemid 44932240)
6. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009;38:411-19.
7. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237-41. (Pubitemid 43372104)
8. Rochdi M, Sabouraud A, Girre C, Venet R, Scherrmann JM. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol. 1994;46:351-4. (Pubitemid 24167384)
9. Nuki G. Colchicine: Its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008;10:218-27.
10. Chappey ON, Niel E, Wautier JL, et al. Colchicine disposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther. 1993;54:360-7. (Pubitemid 23316171)
11. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dosecomparison colchicine study. Arthritis Rheum. 2010;62:1060-8.
12. Terkeltaub RA. Gout. N Engl J Med. 2003;349:1647-55.